Literature DB >> 15685540

Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis.

Gwo-Tzer Ho1, Elaine R Nimmo, Albert Tenesa, Janice Fennell, Hazel Drummond, Craig Mowat, Ian D Arnott, Jack Satsangi.   

Abstract

BACKGROUND AND AIMS: The MDR1 gene encodes P-glycoprotein 170, an efflux transporter that is highly expressed in intestinal epithelial cells. The MDR1 exonic single nucleotide polymorphisms (SNPs) C3435T and G2677T have been shown to correlate with activity/expression of P-glycoprotein 170.
METHODS: This was a case-control analysis of MDR1 C3435T and G2677T SNPs in a large well-characterized Scottish white cohort (335 with ulcerative colitis [UC], 268 with Crohn's disease [CD], and 370 healthy controls). We conducted 2-locus haplotype and detailed univariate and multivariate genotypic-phenotypic analyses.
RESULTS: The MDR1 3435 TT genotype (34.6% vs 26.5%; P = .04; odds ratio [OR], 1.60; 95% confidence interval [95% CI], 1.04-2.44) and T-allelic frequencies (58.2% vs 52.8%; P = .02; OR, 1.28; 95% CI, 1.03-1.58) were significantly higher in patients with UC compared with controls. No association was seen with CD. The association was strongest with extensive UC (TT genotype: 42.4% vs 26.5%; P = .003; OR, 2.64; 95% CI, 1.34-4.99; and T allele: 63.9% vs 52.8%; P = .009; OR, 1.70; 95% CI, 1.24-2.29), and this was also confirmed on multivariate analysis ( P = .007). The G2677T SNP was not associated with UC or CD. These 2 SNPs lie in linkage disequilibrium in our population (D', .8-.9; r 2 , .7-.8). Two-locus haplotypes showed both positive (3435T/G2677 haplotype: P = .03; OR, 1.44) and negative (C3435/2677T haplotype: P = .002; OR, .35) associations with UC. Homozygotes for the haplotype 3435T/G2677 were significantly increased in UC ( P = .017; OR, 8.88; 95% CI, 1.10-71.45).
CONCLUSIONS: Allelic variations of the MDR1 gene determine disease extent as well as susceptibility to UC in the Scottish population. The present data strongly implicate the C3435T SNP, although the 2-locus haplotype data underline the need for further detailed haplotypic studies.

Entities:  

Mesh:

Year:  2005        PMID: 15685540     DOI: 10.1053/j.gastro.2004.11.019

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  44 in total

1.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

Review 2.  Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.

Authors:  Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

3.  DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population.

Authors:  C L Noble; E R Nimmo; H Drummond; L Smith; I D R Arnott; J Satsangi
Journal:  Gut       Date:  2005-04-20       Impact factor: 23.059

Review 4.  Clinical implications of oxidative stress and antioxidant therapy.

Authors:  Gerald W Dryden; Ion Deaciuc; Gavin Arteel; Craig J McClain
Journal:  Curr Gastroenterol Rep       Date:  2005-08

Review 5.  Genetics of inflammatory bowel disease: current status and future directions.

Authors:  Thomas D Walters; Mark S Silverberg
Journal:  Can J Gastroenterol       Date:  2006-10       Impact factor: 3.522

Review 6.  Genetic factors associated with the development of inflammatory bowel disease.

Authors:  Jesus-K Yamamoto-Furusho
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

7.  Evidence for association of OCTN genes and IBD5 with ulcerative colitis.

Authors:  S Waller; M Tremelling; F Bredin; L Godfrey; J Howson; M Parkes
Journal:  Gut       Date:  2005-12-16       Impact factor: 23.059

Review 8.  The future of molecular approaches to inflammatory bowel disease.

Authors:  Boyko Kabakchiev; Smita Halder; Mark S Silverberg
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

9.  Critical role for P-glycoprotein expression in hematopoietic cells in the FVB.Mdr1a(-/-) model of colitis.

Authors:  Elizabeth M Staley; Reed A Dimmitt; Trenton R Schoeb; Scott M Tanner; Robin G Lorenz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-12       Impact factor: 2.839

Review 10.  Inflammatory bowel disease: genetic and epidemiologic considerations.

Authors:  Judy H Cho
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.